ArticleJournal of translational medicine2026
Efficacy and safety evaluation of HyperSperm treatment in human semen samples.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06742437 (Efficacy and Safety of a New Sperm Capacitation Method), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of a New Sperm Capacitation Method: a Prospective in Vitro Study on Semen Samples
Who cites it
1 citing paper in PubMed.
- A multicenter, prospective sibling oocyte study revealed that HyperSpermJournal of translational medicine · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAssisted reproductive technologies (ART) rely on the functional integrity of spermatozoa, which can be affected by in vitro handling and preparation procedures. HyperSperm is a novel sperm treatment medium developed to enhance sperm function and improve clinical outcomes. This study aimed to evaluate the efficacy and safety of HyperSperm in human semen samples from patients undergoing fertility treatment.
methodsA paired analysis was performed on 135 clinical semen samples, each divided into two equal fractions processed using either standard conditions or the HyperSperm protocol. Sperm motility and kinematic parameters were measured with computer-assisted analysis. Safety assessments included sperm viability at baseline and after 24 hours, DNA fragmentation using a fluorescence-based assay, and acrosomal integrity under spontaneous and progesterone-stimulated conditions. Comparisons between paired samples were analyzed using the Wilcoxon matched-pairs signed-rank test.
resultsHyperSperm significantly enhanced sperm kinematic parameters, including curvilinear velocity and amplitude of lateral head displacement, resulting in higher levels of hyperactivated motility. Stratification by semen quality demonstrated that samples with reduced motility showed the greatest functional improvement. HyperSperm did not affect sperm viability or DNA integrity, even after 24 hours of incubation, and preserved acrosomal structure and responsiveness to progesterone. The clinical trial was registered at ClinicalTrials.gov (NCT06742437, December 12th 2024).
conclusionsHyperSperm improves critical sperm functional parameters without compromising cellular viability, DNA stability, or acrosomal integrity. These findings support the safe and effective use of HyperSperm to optimize sperm performance and potentially improve outcomes in assisted reproduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.